UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/792,178	03/03/2004	David E. Francischelli	P-8575.06	4900	
27581 MEDTRONIC	7590 01/09/2008		EXAMINER		
710 MEDTRO	MEDTRONIC, INC. 710 MEDTRONIC PARKWAY NE			VRETTAKOS, PETER J	
MINNEAPOL	IS, MN 55432-9924		ART UNIT PAPER NUMBER		
			3739		
			MAIL DATE	DELIVERY MODE	
			01/09/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)	
Office Action Summary		10/792,178	FRANCISCHELLI ET AL.	
		Examiner	Art Unit	
•	<u>.</u>	Peter J. Vrettakos	3739	
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address	
VVHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ARANDONE.	N. nely filed the mailing date of this communication.	
Status			•	
2a) <u></u> 	Responsive to communication(s) filed on <u>27 Not</u> This action is FINAL . 2b) This Since this application is in condition for allowant closed in accordance with the practice under Ex	action is non-final. ce except for formal matters, pro		
Dienoeiti	ion of Claims	n parte Quayre, 1905 O.D. 11, 40	3 O.G. 213.	
5)	Claim(s) 25-33 and 62-79 is/are pending in the 4a) Of the above claim(s) 62-79 is/are withdraw Claim(s) is/are allowed. Claim(s) 25-33 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examiner The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the d Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner The oath or declaration is objected to by t	election requirement. pted or b) objected to by the Erawing(s) be held in abeyance. See on is required if the drawing(s) is objected.	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
12)	Acknowledgment is made of a claim for foreign part All b) Some * c) None of: 1 Certified copies of the priority documents 2 Certified copies of the priority documents 3 Copies of the certified copies of the priority application from the International Bureau ee the attached detailed Office action for a list of	have been received. have been received in Application by documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage	
l)	(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) eation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	4) Interview Summary (I Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	e	

Application/Control Number:

`10/792,178 Art Unit: 3739

DETAILED ACTION

The action is non-final.

RCE filed 11-27-07.

Claims 25-33 are rejected.

Claims 62-79 are withdrawn.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 25-26 and 28-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Nardella (5,733,281).

Re: claims 25-26, 28, 31: Nardella discloses a method of tissue ablation comprising positioning an electrode (energy delivering electrode, patented claim 1, 12), supplying electrical power (electrosurgical energy, 40), sensing with a sensor (20) the vibration of the tissue (piezoelectric ceramic crystal, patented claim 7; acoustic output signal, patented claim 3) and reducing/halting ("regulating", patented claim 3; power regulation element; col. 8:57-60) power when the vibration reaches a given value.

See col. 2:46-59 for disclosure toward an acoustical detection element, which anticipates detecting vibrations in tissue that is being treated during the ablation procedure. See col. 3:18-23 for disclosure toward regulating the power supplied to the

10/792,178 Art Unit: 3739

device electrode in response to the acoustic output signal, which anticipates reducing power when the "vibration" detected in tissue during ablation treatment reaches a given value.

Re: claims 29, 30: Nardella discloses an output device (130) and an indicator signal (along 128). See figure 2 and col. 8:53-57 for disclosure toward the output device providing output when the sensed vibration is outside a specific/selected range.

Re: claim 32: PVDF in col. 7:36 is a piezoelectric polymer.

Re: claim 33: sensor (20) is integrated with the electrode (12) as depicted in figures 1-3.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 27 is rejected under 35 U.S.C. 103(a) as being unpatentable over Nardella (5,733,281) in view of Nardella (5,334,193).

Nardella ('281) incorporates by reference in col. 9:56 Nardella (5,334,193), which discloses *impedance* feedback control of fluid delivery to treated tissue (see '193 Abstract).

10/792,178

Art Unit: 3739

Nardella ('281) discloses in one embodiment impedance feedback control of power delivery, and in another embodiment acoustic/vibration feedback control of power delivery. As such, Nardella establishes that impedance feedback control is a seamless substitution for acoustic/vibration control and vice versa.

Claim 27 discloses *vibration* feedback control of fluid delivery to treated tissue. The Office argues that Nardella ('281) (impedance/vibration feedback control of power) in light of Nardella ('193) (impedance feedback control of fluid delivery) makes obvious vibration feedback control of fluid delivery to treated tissue thereby making obvious at the time of the Applicant's invention, claim 27, the motivation to add vibration feedback control of fluid to Nardella ('281) to optimize the ablation procedure for reasons seen in Nardella ('193).

Response to Arguments

Applicant's arguments filed 11-27-07 have been fully considered but they are not persuasive. Nardella discloses an ablation method using vibration feedback. The source of the vibration includes that that is self-generated (and not merely that emitted by Nardella's transducer). Nardella detects the effects of energy on tissue (self-generated) such as the generation of steam created during energy application/heat generation. See col. 2: 48-55. Nardella's transducers emit a pulse and the tissue reflects that pulse, which is sensed. Self-generated vibrations due to ablation affect the emitted pulse during the reflection and therefore the vibration feedback system is controlled by self generated vibrations as well as transducer emitted pulses. To say otherwise is to argue

10/792,178

Art Unit: 3739

that the Applicant's ablation causes self-generated waves in the tissue, but Nardella's does not. This defies logic. How does the Applicant's ablation differ from Nardella's?

The waves generated by ablation in Nardella inherently affect the emitted wave from the transducer. As such the rejection stands.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Vrettakos whose telephone number is 571-272-4775. The examiner can normally be reached on M-F 9-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda C. Dvorak can be reached on 571-272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/792,178 Art Unit: 3739

Pete Vrettakos

December 24, 2007

Page 6

PRIMARY EXAMINER